Bisphosphonates
Drug Safety Update
December 2015: Bisphosphonates and very rare reports of osteonecrosis of the external auditory canal. See also see BNF for safety guidance.
June 2011: Bisphosphonates and atypical femoral fractures. See also see BNF for safety guidance.
April 2010: Intravenous zoledronic acid: adverse effects on renal function
November 2009: Bisphosphonates and osteonecrosis of the jaw. See also see BNF for safety guidance.
July 2008: Bisphosphonates and atrial fibrillation
National guidance
TA464 Bisphosphonates for treating osteoporosis, updated July 2019
National Osteoporosis Guideline Group (NOGG) Clinical guideline for the prevention and treatment of osteoporosis, updated September 2021
| Pack | Price |
|---|---|
| 28 tablet (2 x 14 tablets) | £7.50 |
| Pack | Price |
|---|---|
| 4 tablet | £0.95 |
| Pack | Price |
|---|---|
| 28 tablet (2 x 14 tablets) | £24.00 |
| Pack | Price |
|---|---|
| 4 tablet | £1.49 |
An option for osteoporosis only if the patient meets NICE TA464 criteria
| Pack | Price |
|---|---|
| 1 tablet | £1.36 |
| 3 tablet | £7.05 |
| Pack | Price |
|---|---|
| 1 pre-filled disposable injection | £65.40 |
| Pack | Price |
|---|---|
| 4 ampoule |
| Pack | Price |
|---|---|
| 2 ampoule |
| Pack | Price |
|---|---|
| 1 ampoule |